Beneficial interest AvH: 15%
AvH Contact: John-Eric Bertrand
After four years, OncoDNA already works together with more than 3,000 oncologists and around a hundred institutions in more than 50 countries. At year-end 2016, OncoDNA had a team of 35 people, a number that is still growing.
On September 1, 2016, Ackermans & van Haaren became the biggest shareholder (15%) of the company OncoDNA, following the close of a capital round of a total of 7.7 million euros.
In 2016, OncoDNA officially launched its new solution, OncoTRACE. This first truly personalized test in the world uses a simple blood sample to monitor the evolution of a patient’s cancer, so that the efficacy of the treatment can be assessed quickly.
OncoSHARE, the innovative communication, sharing and networking platform, brings together the biggest online community in the field of cancer, with more than 10,000 users (oncologists, patients and people close to them).
OncoDNA wants to accelerate its international growth and keep expanding its network of oncologists, for example by the launch throughout Europe of the SaaS (Software as a Service) solution OncoKDM. This will give a large number of cancer treatment centres worldwide access to OncoDNA’s database and expertise. Several important partnerships have already taken shape or are about to do so. OncoDNA will build on its first successes of 2016 to develop its network of partners and strengthen ties with the pharmaceutical industry.
A new solution, OncoSTRAT&GO, will be officially launched in 2017. It makes tumour analysis possible based on a biopsy of the primary tumour or a metastasis, also using a blood sample. Two major projects will be launched with the support of the Walloon Region. The first, ARCHE, will demonstrate the clinical efficacy of OncoSTRAT&GO. More than 1,200 patients will be involved. The second major project in bioinformatics will be announced in the course of 2017.
Oncology is the first therapeutic field that applies personalized treatments by combining diagnostic tools, knowledge bases and medication therapies. OncoDNA is currently well placed to become the leading European player in this scientific revolution that benefits patients.